Application of 18F-FDOPA PET and Magnetic Resonance Spectroscopy (MRS) With HCV and PD

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to investigate the evidence of dopaminergic toxicity causing by HCV infection using 18F-FDOPA PET and MRS as imaging biomarkers.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: National Taiwan University Hospital
• Treatments: Dihydroxyphenylalanine

Criteria

Inclusion Criteria:

• Test Group

1. Age：above 20 years old with HBV or HCV subjects.

2. Patient agrees to participate in the study and receive UPDRS, MMSE, BDI II, MRI and PET imaging.

• Control Group

1. Age：above 20 years old without carriers of Hepatitis B and C (ex. fatty liver), and no known neurological (ex. stroke, Parkinson's disease and degenerative neuropathy, etc.) and mental illness.

2. Patient agrees to participate in the study and receive UPDRS, MMSE, BDI II, MRI and PET imaging.

Exclusion Criteria:

1. Patients could not receive PET and MRI studies, including panic mood to MRI study, allergy to contrast medium, hemodynamic instability.

2. Patients with pregnancy or recently having a plan for pregnancy.

3. Patient or family who does not agree to participate in the study